

J Antoni Ramos-Quiroga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7957543/publications.pdf>

Version: 2024-02-01

220
papers

18,150
citations

36303

51
h-index

17592

121
g-index

251
all docs

251
docs citations

251
times ranked

19351
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	21.4	2,067
2	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	21.4	1,191
3	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
4	Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 2015, 1, 15020.	30.5	959
5	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935
6	Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 2015, 18, 199-209.	14.8	701
7	European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry, 2010, 10, 67.	2.6	660
8	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	21.4	629
9	Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry, the, 2017, 4, 310-319.	7.4	565
10	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
11	CWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature Neuroscience, 2018, 21, 1161-1170.	14.8	436
12	Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 2018, 28, 1059-1088.	0.7	398
13	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 2019, 56, 14-34.	0.2	330
14	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5154-E5163.	7.1	299
15	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. American Journal of Psychiatry, 2019, 176, 531-542.	7.2	261
16	A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Molecular Psychiatry, 2010, 15, 1053-1066.	7.9	245
17	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. American Journal of Human Genetics, 2015, 96, 283-294.	6.2	225
18	Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs, 2011, 25, 157-169.	5.9	192

#	ARTICLE	IF	CITATIONS
19	Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD. <i>Neuropsychopharmacology</i> , 2010, 35, 656-664.	5.4	180
20	A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2008, 63, 981-989.	1.3	167
21	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. <i>Drug and Alcohol Dependence</i> , 2014, 134, 158-166.	3.2	150
22	An independent components and functional connectivity analysis of resting state fMRI data points to neural network dysregulation in adult ADHD. <i>Human Brain Mapping</i> , 2014, 35, 1261-1272.	3.6	147
23	A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2018, 83, 1044-1053.	1.3	146
24	Exploration of 19 serotonergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. <i>Molecular Psychiatry</i> , 2009, 14, 71-85.	7.9	141
25	The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. <i>Biological Psychiatry</i> , 2020, 88, 169-184.	1.3	137
26	Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32,330 subjects from the International Cannabis Consortium. <i>Translational Psychiatry</i> , 2016, 6, e769-e769.	4.8	136
27	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
28	Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. <i>Drug and Alcohol Dependence</i> , 2013, 132, 587-596.	3.2	135
29	Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>IASP</scp> study. <i>Addiction</i> , 2014, 109, 262-272.	3.3	129
30	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , 2022, 91, 313-327.	1.3	114
31	The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents. <i>International Archives of Occupational and Environmental Health</i> , 2012, 85, 837-847.	2.3	112
32	Criteria and Concurrent Validity of DIVA 2.0: A Semi-Structured Diagnostic Interview for Adult ADHD. <i>Journal of Attention Disorders</i> , 2019, 23, 1126-1135.	2.6	106
33	Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study. <i>Genes, Brain and Behavior</i> , 2011, 10, 149-157.	2.2	103
34	Association Study of 10 Genes Encoding Neurotrophic Factors and Their Receptors in Adult and Child Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2008, 63, 935-945.	1.3	93
35	Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines. <i>Current Medical Research and Opinion</i> , 2013, 29, 1093-1104.	1.9	92
36	Comorbid Attention-Deficit/Hyperactivity Disorder in Borderline Patients Defines an Impulsive Subtype of Borderline Personality Disorder. <i>Journal of Personality Disorders</i> , 2010, 24, 812-822.	1.4	84

#	ARTICLE	IF	CITATIONS
37	Response inhibition and reward anticipation in medication-naïve adults with attention-deficit/hyperactivity disorder: A within-subject case-control neuroimaging study. Human Brain Mapping, 2012, 33, 2350-2361.	3.6	78
38	Analysis of two language-related genes in autism. Psychiatric Genetics, 2013, 23, 82-85.	1.1	78
39	New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 459-470.	1.7	78
40	COVID-19 pandemic effects in people with Autism Spectrum Disorder and their caregivers: Evaluation of social distancing and lockdown impact on mental health and general status. Research in Autism Spectrum Disorders, 2021, 83, 101757.	1.5	74
41	Shared genetic background between children and adults with attention deficit/hyperactivity disorder. Neuropsychopharmacology, 2020, 45, 1617-1626.	5.4	72
42	Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 124, 100-123.	6.1	71
43	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
44	Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction, 2007, 102, 1871-1887.	3.3	65
45	Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder. Human Brain Mapping, 2010, 31, 1942-1950.	3.6	64
46	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure. Human Brain Mapping, 2022, 43, 37-55.	3.6	61
47	Psychoeducation for Adults With Attention Deficit Hyperactivity Disorder vs. Cognitive Behavioral Group Therapy. Journal of Nervous and Mental Disease, 2013, 201, 894-900.	1.0	60
48	Case-Control Study of Six Genes Asymmetrically Expressed in the Two Cerebral Hemispheres: Association of BAIAP2 with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2009, 66, 926-934.	1.3	59
49	Case-Control Genome-Wide Association Study of Persistent Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as a Novel Susceptibility Gene for the Disorder. Neuropsychopharmacology, 2015, 40, 915-926.	5.4	59
50	Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. Molecular Psychiatry, 2020, 25, 2493-2503.	7.9	59
51	Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. The Cochrane Library, 2011, , CD007813.	2.8	58
52	Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1267-1275.	2.1	56
53	Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe. BMC Psychiatry, 2015, 15, 242.	2.6	54
54	The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population. International Journal of Methods in Psychiatric Research, 2013, 22, 232-244.	2.1	53

#	ARTICLE	IF	CITATIONS
55	Genome-wide copy number variation analysis in adult attention-deficit and hyperactivity disorder. <i>Journal of Psychiatric Research</i> , 2014, 49, 60-67.	3.1	50
56	DIRAS2 is Associated with Adult ADHD, Related Traits, and Co-Morbid Disorders. <i>Neuropsychopharmacology</i> , 2011, 36, 2318-2327.	5.4	49
57	Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. <i>European Neuropsychopharmacology</i> , 2013, 23, 1078-1084.	0.7	49
58	Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate. <i>CNS Drugs</i> , 2008, 22, 603-611.	5.9	47
59	Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 275-282.	0.5	46
60	Validez de criterio y concurrente de la versión española de la Conners Adult ADHD Diagnostic Interview for DSM-IV. <i>Revista De Psiquiatría Y Salud Mental</i> , 2012, 5, 229-235.	1.8	45
61	Training-induced neuroanatomical plasticity in ADHD: A tensor-based morphometric study. <i>Human Brain Mapping</i> , 2011, 32, 1741-1749.	3.6	43
62	Attention deficit hyperactivity disorder in cocaine-dependent adults: A psychiatric comorbidity analysis. <i>American Journal on Addictions</i> , 2013, 22, 466-473.	1.4	42
63	Genome-wide analyses of aggressiveness in attention-deficit hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 733-747.	1.7	40
64	Analysis of structural brain asymmetries in attention-deficit/hyperactivity disorder in 39 datasets. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 1202-1219.	5.2	40
65	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). <i>European Neuropsychopharmacology</i> , 2013, 23, 1463-1473.	0.7	38
66	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	2.6	38
67	Psychological impact and social support in pregnant women during lockdown due to SARS-CoV2 pandemic: A cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1026-1033.	2.8	37
68	Neurotransmitter systems and neurotrophic factors in autism: association study of 37 genes suggests involvement of DDC. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 516-527.	2.6	36
69	Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 389-399.	4.5	35
70	Brain abnormalities in adults with Attention Deficit Hyperactivity Disorder revealed by voxel-based morphometry. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 41-47.	1.8	35
71	Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene <i>Adgrl3</i> : Evidence for dopamine transporter dysregulation. <i>Neuropharmacology</i> , 2019, 156, 107557.	4.1	34
72	Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. <i>Journal of Attention Disorders</i> , 2019, 23, 1438-1453.	2.6	34

#	ARTICLE	IF	CITATIONS
73	Sleep in adults with autism spectrum disorder and attention deficit/hyperactivity disorder: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 38, 1-24.	0.7	33
74	Transcranial direct current stimulation in Autism Spectrum Disorder: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2021, 48, 89-109.	0.7	33
75	Laminar Thickness Alterations in the Fronto-Parietal Cortical Mantle of Patients with Attention-Deficit/Hyperactivity Disorder. <i>PLoS ONE</i> , 2012, 7, e48286.	2.5	32
76	IL-6 and TNF- α in unmedicated adults with ADHD: Relationship to cortisol awakening response. <i>Psychoneuroendocrinology</i> , 2017, 79, 67-73.	2.7	32
77	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. <i>BMC Psychiatry</i> , 2018, 18, 40.	2.6	32
78	Predictors of treatment outcome in adults with ADHD treated with OROS [®] methylphenidate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 554-560.	4.8	31
79	Preliminary evidence for association of genetic variants in pri-miR-34b/c and abnormal miR-34c expression with attention deficit and hyperactivity disorder. <i>Translational Psychiatry</i> , 2016, 6, e879-e879.	4.8	31
80	Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. <i>Neuropsychopharmacology</i> , 2019, 44, 890-897.	5.4	31
81	Genetic association study of childhood aggression across raters, instruments, and age. <i>Translational Psychiatry</i> , 2021, 11, 413.	4.8	31
82	Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 553-567.	2.8	30
83	Emotional lability: The discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. <i>Comprehensive Psychiatry</i> , 2014, 55, 1712-1719.	3.1	30
84	ADGRL3 (LPHN3) variants predict substance use disorder. <i>Translational Psychiatry</i> , 2019, 9, 42.	4.8	29
85	Candidate system analysis in ADHD: Evaluation of nine genes involved in dopaminergic neurotransmission identifies association with <i>DRD1</i> . <i>World Journal of Biological Psychiatry</i> , 2012, 13, 281-292.	2.6	28
86	Evaluation of common variants in 16 genes involved in the regulation of neurotransmitter release in ADHD. <i>European Neuropsychopharmacology</i> , 2013, 23, 426-435.	0.7	28
87	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. <i>European Addiction Research</i> , 2020, 26, 223-232.	2.4	28
88	Association study of 37 genes related to serotonin and dopamine neurotransmission and neurotrophic factors in cocaine dependence. <i>Genes, Brain and Behavior</i> , 2013, 12, 39-46.	2.2	27
89	Exome chip analyses in adult attention deficit hyperactivity disorder. <i>Translational Psychiatry</i> , 2016, 6, e923-e923.	4.8	27
90	Alcohol use disorders and ADHD. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 648-660.	6.1	27

#	ARTICLE	IF	CITATIONS
91	Strengths and Difficulties Questionnaire: Psychometric Properties and Normative Data for Spanish 5- to 17-Year-Olds. <i>Assessment</i> , 2021, 28, 1445-1458.	3.1	27
92	Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. <i>Psychological Medicine</i> , 2012, 42, 195-204.	4.5	26
93	Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 268-281.	2.6	26
94	Extended-release guanfacine hydrochloride in 6- to 17-year olds with ADHD: a randomised withdrawal maintenance of efficacy study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2016, 57, 717-728.	5.2	26
95	Childhood trauma exposure in substance use disorder patients with and without ADHD. <i>Addictive Behaviors</i> , 2017, 65, 118-124.	3.0	26
96	Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in adolescents and young adults with attention-deficit / hyperactivity disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 140.	1.6	26
97	Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2011, 25, 17-36.	5.9	25
98	Cortisol responses in children and adults with attention deficit hyperactivity disorder (ADHD): a possible marker of inhibition deficits. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2012, 4, 63-75.	1.7	25
99	Early-age clinical and developmental features associated to Substance Use Disorders in Attention-Deficit/Hyperactivity Disorder in Adults. <i>Comprehensive Psychiatry</i> , 2014, 55, 639-649.	3.1	25
100	SLC2A3 single nucleotide polymorphism and duplication influence cognitive processing and population-specific risk for attention-deficit/hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 798-809.	5.2	25
101	Differences in the association between childhood trauma history and borderline personality disorder or attention deficit/hyperactivity disorder diagnoses in adulthood. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 541-549.	3.2	25
102	Clinical Validation of Eye Vergence as an Objective Marker for Diagnosis of ADHD in Children. <i>Journal of Attention Disorders</i> , 2019, 23, 599-614.	2.6	25
103	Genetic overlap and causality between substance use disorder and attention-deficit and hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2021, 186, 140-150.	1.7	25
104	Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder. <i>Translational Psychiatry</i> , 2021, 11, 382.	4.8	25
105	Quantitative MR analysis of caudate abnormalities in pediatric ADHD: Proposal for a diagnostic test. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 238-243.	1.8	24
106	Genome-wide association meta-analysis of age at first cannabis use. <i>Addiction</i> , 2018, 113, 2073-2086.	3.3	24
107	Stimulant drugs trigger transient volumetric changes in the human ventral striatum. <i>Brain Structure and Function</i> , 2014, 219, 23-34.	2.3	23
108	Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder. <i>Pharmacogenomics Journal</i> , 2017, 17, 98-104.	2.0	23

#	ARTICLE	IF	CITATIONS
109	Treatment retention and abstinence of patients with substance use disorders according to addiction severity and psychiatry comorbidity: A six-month follow-up study in an outpatient unit. Addictive Behaviors, 2021, 117, 106832.	3.0	23
110	Exploring <i>DRD4</i> and its interaction with <i>SLC6A3</i> as possible risk factors for adult ADHD: A meta-analysis in four European populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 600-612.	1.7	22
111	Psychiatric factors affecting recovery after a long term treatment program for substance use disorder. Psychiatry Research, 2019, 276, 283-289.	3.3	22
112	Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study. European Journal of Psychiatry, 2013, 27, 185-205.	1.3	22
113	Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity?. Neuroscience and Biobehavioral Reviews, 2022, 132, 1157-1180.	6.1	22
114	Cortisol Response to Stress in Adults with Attention Deficit Hyperactivity Disorder. International Journal of Neuropsychopharmacology, 2015, 18, pyv027.	2.1	21
115	Functional Imaging Changes in the Medial Prefrontal Cortex in Adult ADHD. Journal of Attention Disorders, 2018, 22, 679-693.	2.6	21
116	Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. Trials, 2020, 21, 161.	1.6	21
117	Neurodevelopmental disorders among Spanish school-age children: prevalence and sociodemographic correlates. Psychological Medicine, 2022, 52, 3062-3072.	4.5	21
118	Effectiveness of a Transdiagnostic Guided Internet-Delivered Protocol for Emotional Disorders Versus Treatment as Usual in Specialized Care: Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e18220.	4.3	21
119	On the role of <i>NOS1</i> <i>ex1</i> VNTR in ADHD allelic, subgroup, and meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 445-458.	1.7	20
120	Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2009, 5, 457.	2.2	19
121	Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 666, 44-49.	1.0	18
122	Common variants in the TPH1 and TPH2 regions are not associated with persistent ADHD in a combined sample of 1,636 adult cases and 1,923 controls from four European populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1008-1015.	1.7	18
123	Personality profile of adult ADHD: The alternative five factor model. Psychiatry Research, 2012, 198, 130-134.	3.3	18
124	Dopamine receptor DRD4 gene and stressful life events in persistent attention deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 480-491.	1.7	18
125	Time and psychostimulants: Opposing long-term structural effects in the adult ADHD brain. A longitudinal MR study. European Neuropsychopharmacology, 2017, 27, 1238-1247.	0.7	18
126	Alcohol use disorder and cognitive impairment in old age patients: A 6 months follow-up study in an outpatient unit in Barcelona. Psychiatry Research, 2018, 261, 361-366.	3.3	18

#	ARTICLE	IF	CITATIONS
127	Changes in the Mental Health of Children and Adolescents during the COVID-19 Lockdown: Associated Factors and Life Conditions. International Journal of Environmental Research and Public Health, 2022, 19, 4120.	2.6	18
128	Serum Brain-Derived Neurotrophic Factor Levels and Cocaine-Induced Transient Psychotic Symptoms. Neuropsychobiology, 2013, 68, 146-155.	1.9	17
129	Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology, 2014, 231, 1389-1395.	3.1	17
130	Criteria and Concurrent Validity of Adult ADHD Section of the Psychiatry Research Interview for Substance and Mental Disorders. Journal of Attention Disorders, 2015, 19, 999-1006.	2.6	17
131	Validación al español de la ADHD Rating Scale (ADHD-RS) en adultos: relevancia de los subtipos clínicos. Revista De Psiquiatría Y Salud Mental, 2017, 10, 185-191.	1.8	17
132	Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. European Child and Adolescent Psychiatry, 2018, 27, 1283-1294.	4.7	17
133	Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing. Molecular Psychiatry, 2020, 25, 2047-2057.	7.9	17
134	DISC1 in adult ADHD patients: An association study in two European samples. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 227-234.	1.7	16
135	Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 719-727.	3.2	16
136	Insomnia Disorder in Adult Attention-Deficit/Hyperactivity Disorder Patients: Clinical, Comorbidity, and Treatment Correlates. Frontiers in Psychiatry, 2021, 12, 663889.	2.6	16
137	Candidate pathway association study in cocaine dependence: The control of neurotransmitter release. World Journal of Biological Psychiatry, 2012, 13, 126-134.	2.6	15
138	The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities. European Addiction Research, 2020, 26, 173-178.	2.4	15
139	Electrophysiological Brain Changes Associated With Cognitive Improvement in a Pediatric Attention Deficit Hyperactivity Disorder Digital Artificial Intelligence-Driven Intervention: Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e25466.	4.3	15
140	An association study of sequence variants in the forkhead box P2 (FOXP2) gene and adulthood attention-deficit/hyperactivity disorder in two European samples. Psychiatric Genetics, 2012, 22, 155-160.	1.1	14
141	The Conners™ Adult ADHD Rating Scales™ Short Self-Report and Observer Forms. Journal of Attention Disorders, 2014, 18, 671-679.	2.6	14
142	Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. Scientific Reports, 2018, 8, 1881.	3.3	14
143	Stepwise functional connectivity reveals altered sensory-multimodal integration in medication-naïve adults with attention deficit hyperactivity disorder. Human Brain Mapping, 2019, 40, 4645-4656.	3.6	14
144	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14

#	ARTICLE	IF	CITATIONS
145	Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults. <i>Translational Psychiatry</i> , 2020, 10, 199.	4.8	14
146	Is alexithymia related to retention and relapses in patients with substance use disorders?: A one year follow-up study. <i>Addictive Behaviors</i> , 2021, 113, 106681.	3.0	14
147	Cognitive reserve in mental disorders. <i>European Neuropsychopharmacology</i> , 2021, 49, 113-115.	0.7	14
148	The impact of psychopathology on academic performance in school-age children and adolescents. <i>Scientific Reports</i> , 2022, 12, 4291.	3.3	14
149	Presence of Distractor Improves Time Estimation Performance in an Adult ADHD Sample. <i>Journal of Attention Disorders</i> , 2020, 24, 1530-1537.	2.6	13
150	Continuity of Genetic Risk for Aggressive Behavior Across the Life-Course. <i>Behavior Genetics</i> , 2021, 51, 592-606.	2.1	13
151	Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes. <i>International Journal of Epidemiology</i> , 2023, 52, 386-402.	1.9	13
152	Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2012, 5, 229-235.	0.3	12
153	Association of the PLCB1 gene with drug dependence. <i>Scientific Reports</i> , 2017, 7, 10110.	3.3	12
154	Psychiatric Comorbidity and Addiction Severity Differences in Patients With ADHD Seeking Treatment for Cannabis or Cocaine Use Disorders. <i>Journal of Attention Disorders</i> , 2021, 25, 978-988.	2.6	12
155	Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study. <i>European Addiction Research</i> , 2015, 21, 188-194.	2.4	11
156	Are patients with bipolar disorder and comorbid attention deficit hyperactivity disorder more neurocognitively impaired?. <i>Bipolar Disorders</i> , 2017, 19, 637-650.	1.9	11
157	Gene-wide Association Study Reveals RNF122 Ubiquitin Ligase as a Novel Susceptibility Gene for Attention Deficit Hyperactivity Disorder. <i>Scientific Reports</i> , 2017, 7, 5407.	3.3	11
158	Functional impairment in adult bipolar disorder with ADHD. <i>Journal of Affective Disorders</i> , 2018, 227, 117-125.	4.1	11
159	Sleep disturbances in autism spectrum disorder without intellectual impairment: relationship with executive function and psychiatric symptoms. <i>Sleep Medicine</i> , 2021, 83, 106-114.	1.6	11
160	Psychosocial Profiles of Adults with ADHD: A Comparative Study of Prison and Outpatient Psychiatric Samples. <i>European Journal of Psychology Applied To Legal Context</i> , 2018, 11, 41-49.	4.6	11
161	COVID-19 Lockdown and Consumption Patterns among Substance Use Disorder Outpatients: A Multicentre Study. <i>European Addiction Research</i> , 2022, 28, 243-254.	2.4	11
162	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. <i>Biological Psychiatry</i> , 2022, 92, 299-313.	1.3	11

#	ARTICLE	IF	CITATIONS
163	Psychopathology and traffic violations in subjects who have lost their driving license. <i>Comprehensive Psychiatry</i> , 2017, 76, 45-55.	3.1	10
164	Impact of COVID-19 on Families of Pediatric Solid Organ Transplant Recipients. <i>Journal of Pediatric Psychology</i> , 2021, 46, 927-938.	2.1	10
165	Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder. <i>European Journal of Psychiatry</i> , 2013, 27, 206-224.	1.3	9
166	Cortisol awakening response in adults with attention deficit hyperactivity disorder: Subtype differences and association with the emotional lability. <i>European Neuropsychopharmacology</i> , 2016, 26, 1140-1149.	0.7	9
167	The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. <i>Journal of Attention Disorders</i> , 2019, 23, 1514-1525.	2.6	9
168	Polygenic association between attention-deficit/hyperactivity disorder liability and cognitive impairments. <i>Psychological Medicine</i> , 2022, 52, 3150-3158.	4.5	9
169	Catatonia Related to Cannabis and Synthetic Cannabinoids: A Review. <i>Journal of Dual Diagnosis</i> , 2021, 17, 159-171.	1.2	9
170	Psychotherapeutic interventions specifically developed for NSSI in adolescence: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 58, 86-98.	0.7	9
171	Prevalence and Psychosocial Correlates of ADHD Symptoms in Young Adulthood: A French Population-Based Study. <i>Journal of Attention Disorders</i> , 2018, 22, 167-181.	2.6	8
172	Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders. <i>European Addiction Research</i> , 2020, 26, 191-200.	2.4	8
173	Eye Vergence Responses During an Attention Task in Adults With ADHD and Clinical Controls. <i>Journal of Attention Disorders</i> , 2021, 25, 1302-1310.	2.6	8
174	The Impact of Psychosis on Sexual Functioning: A Systematic Review. <i>Journal of Sexual Medicine</i> , 2021, 18, 457-466.	0.6	8
175	OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1121-1131.	2.8	7
176	The Impact of Emotional Lability Symptoms During Childhood in Adults With ADHD. <i>Journal of Attention Disorders</i> , 2018, 22, 581-590.	2.6	7
177	Benzodiazepine Use Disorder and Cognitive Impairment in Older Patients: A Six-Month-Follow-Up Study in an Outpatient Unit in Barcelona. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 844-852.	1.0	7
178	Family Functioning and Parental Bonding During Childhood in Adults Diagnosed With ADHD. <i>Journal of Attention Disorders</i> , 2019, 23, 57-64.	2.6	7
179	Transcriptome profiling in adult attention-deficit hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2020, 41, 160-166.	0.7	7
180	Dog-Assisted Therapy for Children and Adolescents With Fetal Alcohol Spectrum Disorders a Randomized Controlled Pilot Study. <i>Frontiers in Psychology</i> , 2020, 11, 1080.	2.1	7

#	ARTICLE	IF	CITATIONS
181	The role of environmental influences in the complex relationship between borderline personality disorder and attention-deficit/hyperactivity disorder: review of recent findings. <i>Borderline Personality Disorder and Emotion Dysregulation</i> , 2020, 7, 2.	2.6	7
182	Online interventions for cannabis use among adolescents and young adults: Systematic review and meta-analysis. <i>Microbial Biotechnology</i> , 2022, 16, 821-844.	1.7	7
183	A Multicenter Study on the Impact of Gender, Age, and Dual Diagnosis on Substance Consumption and Mental Health Status in Outpatients Treated for Substance Use Disorders During COVID-19 Lockdown. <i>Journal of Dual Diagnosis</i> , 2022, 18, 71-80.	1.2	7
184	Lack of association between the LPR and VNTR polymorphisms of the serotonin transporter gene and cocaine dependence in a Spanish sample. <i>Psychiatry Research</i> , 2013, 210, 1287-1289.	3.3	6
185	Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). <i>European Neuropsychopharmacology</i> , 2019, 29, 795-802.	0.7	6
186	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, , .	1.8	6
187	Integrating genomics and transcriptomics: Towards deciphering ADHD. <i>European Neuropsychopharmacology</i> , 2021, 44, 1-13.	0.7	6
188	Alexithymia in Patients With Substance Use Disorders and Its Relationship With Psychiatric Comorbidities and Health-Related Quality of Life. <i>Frontiers in Psychiatry</i> , 2021, 12, 659063.	2.6	6
189	Delphi Consensus on Attention Deficit Hyperactivity Disorder (ADHD): evaluation by a panel of experts. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 231-43.	0.1	6
190	Spanish validation of the adult Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS): Relevance of clinical subtypes. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 185-191.	0.3	5
191	End of Life Intervention Program During COVID-19 in Vall d'Hebron University Hospital. <i>Frontiers in Psychiatry</i> , 2021, 12, 608973.	2.6	5
192	A Web-Based App for Emotional Management During the COVID-19 Pandemic: Platform Development and Retrospective Analysis of its Use Throughout Two Waves of the Outbreak in Spain. <i>JMIR Formative Research</i> , 2022, 6, e27402.	1.4	5
193	Impulsivity: current and future trends in pharmacological treatment. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1367-1369.	2.8	4
194	Toward a Better Understanding of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 119-120.	0.5	4
195	Early developmental, temperamental and educational problems in "substance use disorder"™ patients with and without ADHD. Does ADHD make a difference?. <i>Addictive Behaviors Reports</i> , 2015, 2, 13-18.	1.9	4
196	Meta-analysis of the DRD5 VNTR in persistent ADHD. <i>European Neuropsychopharmacology</i> , 2016, 26, 1527-1532.	0.7	4
197	Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample. <i>Drug and Alcohol Dependence</i> , 2018, 187, 358-362.	3.2	4
198	Functioning assessment short test (FAST): validity and reliability in adults with Autism Spectrum Disorder. <i>BMC Psychiatry</i> , 2021, 21, 321.	2.6	4

#	ARTICLE	IF	CITATIONS
199	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. <i>Journal of Affective Disorders</i> , 2022, 302, 83-93.	4.1	4
200	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 36-50.	4.5	4
201	Help Seeking of Highly Specialized Mental Health Treatment before and during the COVID-19 Pandemic among Health Professionals. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3665.	2.6	4
202	Prevalence of attention deficit/hyperactivity disorder symptoms in outpatient adolescents and young adults with other psychiatric disorders refractory to previous treatments. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2014, 7, 104-112.	0.3	3
203	Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110221.	2.7	3
204	Medically Serious Suicide Attempts in Personality Disorders. <i>Journal of Clinical Medicine</i> , 2021, 10, 4186.	2.4	3
205	Diagn�stico dual en m�dicos residentes: una revisi�n sistem�tica. <i>Revista De Psicolog�a De La Salud</i> , 2020, 32, 281.	0.5	3
206	The dynamical association between physical activity and affect in the daily life of individuals with ADHD. <i>European Neuropsychopharmacology</i> , 2022, 57, 69-74.	0.7	3
207	Response to Cunill <i>et al</i>.. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 435-436.	1.9	2
208	Sex differences in an old adult sample with substance use disorder: A 6 months follow-up study. <i>Psychiatry Research</i> , 2018, 270, 1157-1165.	3.3	2
209	Just��time response to reward as a function of ADHD symptom severity. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 731-740.	1.8	2
210	Expert recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD). <i>Actas Espanolas De Psiquiatria</i> , 2014, 42 Suppl, 1-16.	0.1	2
211	Attention deficit hyperactivity disorder symptoms and cannabis use after 1 year among students of the i-Share cohort. <i>European Psychiatry</i> , 2022, 65, 1-18.	0.2	2
212	Adult ADHD: an area lacking in clinical research?. <i>Clinical Investigation</i> , 2013, 3, 803-805.	0.0	1
213	Exploring allele specific methylation in drug dependence susceptibility. <i>Journal of Psychiatric Research</i> , 2021, 136, 474-482.	3.1	1
214	Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder. <i>Scientific Reports</i> , 2021, 11, 2373.	3.3	1
215	Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study. <i>Psychopharmacology Bulletin</i> , 2019, 49, 92-97.	0.0	1
216	Fear Conditioning Deficits in Children and Adolescents with Psychopathic Traits: a Study in a Clinical Population. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2022, 44, 11-25.	1.2	1

#	ARTICLE	IF	CITATIONS
217	Quinolone-induced psychosis: an updated review. <i>Actas Espanolas De Psiquiatria</i> , 2020, 48, 126-37.	0.1	1
218	Retrospective symptoms and learning difficulties predicting ADHD in adults: Differences between prison inmates and the clinical population. <i>Scandinavian Journal of Psychology</i> , 2021, 62, 301-311.	1.5	0
219	Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	3.2	0
220	Three-year prevalence of self-harm behaviors among the reasons for emergency visits of children and adolescents. <i>Actas Espanolas De Psiquiatria</i> , 2021, 49, 35-42.	0.1	0